EGFR and non-small cell lung carcinoma: Therefore, based on CONVINCE results, icotinib was approved by the China Food and Drug Administration (CFDA) in June 2011 as a first-line treatment, enriching the EGFR-mutated NSCLC therapeutic armamentarium.